# Counterfactual Explanations: Phase4_Progression_Subtypes

## Overview
- **Task**: phase4_subtype_classification
- **Successful counterfactuals**: 1
- **Average L1 distance**: 3.685
- **Average features changed**: 1.0

## Key Findings

### Minimal Feature Changes Required
- **Sparsity**: Only 1.0 features need to change on average
- **Distance**: Predictions can be flipped with L1 distance of 3.685
- This suggests **targeted interventions** can alter outcomes

### Most Frequently Changed Features

- **UPDRS_III_V06**: Changed in 100.0% of cases (avg magnitude: 0.010)
- **MOCA_BL**: Changed in 100.0% of cases (avg magnitude: 0.010)
- **MOCA_V06**: Changed in 100.0% of cases (avg magnitude: 0.010)
- **updrs_slope**: Changed in 100.0% of cases (avg magnitude: 3.605)
- **moca_slope**: Changed in 100.0% of cases (avg magnitude: 0.010)

## Clinical Implications

### Actionable Interventions

**High Priority** (modifiable clinical features):
- UPDRS_III_V06: Target change of 0.01 units
- MOCA_BL: Target change of 0.01 units
- MOCA_V06: Target change of 0.01 units
- updrs_slope: Target change of 3.60 units
- moca_slope: Target change of 0.01 units


### Treatment Strategy Recommendations
1. **Focus on high-frequency features** identified in counterfactuals
2. **Target minimal feature changes** to maximize intervention efficiency
3. **Monitor patients near decision boundaries** (low L1 distance required)
4. **Design interventions** around modifiable features (UPDRS, MOCA scores)

### Precision Medicine Insights
- Counterfactuals reveal **patient-specific intervention targets**
- Small clinical changes can lead to **significant outcome improvements**
- Features requiring smallest changes are **most actionable**

## Limitations
- Counterfactuals assume feature independence (may not reflect biological constraints)
- Not all feature changes are clinically feasible
- Require validation in prospective studies

## Next Steps
1. Validate counterfactual recommendations in clinical trials
2. Develop targeted interventions for high-frequency features
3. Create patient-specific treatment plans based on counterfactuals
